MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

MDT

89.25

-0.49%↓

VEEV

279.43

-1.02%↓

A

113.17

-5.79%↓

WBA

11.5

-0.09%↓

HQY

96.22

-1.19%↓

Search

Bio-Rad Laboratories Inc

Gesloten

SectorGezondheidszorg

247.17 -1.4

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

246.46

Max

252.29

Belangrijke statistieken

By Trading Economics

Inkomsten

780M

64M

Verkoop

-82M

585M

EPS

2.54

Winstmarge

10.933

Werknemers

7,700

EBITDA

75M

134M

Aanbevelingen

By TipRanks

Aanbevelingen

Strong Buy

12 Maanden Prognose

+28.78% upside

Dividenden

By Dow Jones

Volgende Winsten

31 jul 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

232M

6.8B

Vorige openingsprijs

248.57

Vorige sluitingsprijs

247.17

Nieuwssentiment

By Acuity

50%

50%

148 / 376 Rangschikking in Healthcare

Technische score

By Trading Central

Vertrouwen

Very Strong Bearish Evidence

Bio-Rad Laboratories Inc Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

14 jul 2025, 22:07 UTC

Belangrijke Marktbewegers

Trade Desk Rises on S&P 500 Inclusion

14 jul 2025, 17:06 UTC

Belangrijke Marktbewegers

Crypto Assets Rally Ahead of Possible U.S. Legislation

14 jul 2025, 16:47 UTC

Acquisities, Fusies, Overnames

NatWest to Sell Stake in Permanent TSB

14 jul 2025, 23:46 UTC

Marktinformatie

Nikkei May Rise as Yen Weakens -- Market Talk

14 jul 2025, 23:38 UTC

Marktinformatie

Gold Edges Higher Ahead of U.S. CPI Data -- Market Talk

14 jul 2025, 23:37 UTC

Marktinformatie

ANZ's Institutional Earnings Likely to Weigh on Outlook -- Market Talk

14 jul 2025, 23:29 UTC

Marktinformatie

South32 Bull Eyes Possible Last-Minute Power Deal for Mozal -- Market Talk

14 jul 2025, 23:29 UTC

Marktinformatie

Global Energy Roundup: Market Talk

14 jul 2025, 23:02 UTC

Winsten

China Vanke: Additional Provision for Asset Impairment Also Among Factors Weighing on Results >000002.SZ

14 jul 2025, 23:02 UTC

Winsten

China Vanke: Weakness in Overall China Real-Estate Sector Weighed on Results >000002.SZ

14 jul 2025, 23:02 UTC

Winsten

China Vanke 1H Loss Was CNY9.85B >000002.SZ

14 jul 2025, 23:01 UTC

Winsten

China Vanke Sees 1H Loss CNY10.0B-Loss CNY12.0B >000002.SZ

14 jul 2025, 23:01 UTC

Winsten

China Vanke Expects 1H Loss to Widen >000002.SZ

14 jul 2025, 20:50 UTC

Marktinformatie

Tech, Media & Telecom Roundup: Market Talk

14 jul 2025, 20:50 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

14 jul 2025, 20:07 UTC

Marktinformatie

Cloud Computing Giants Will Be the Winner from Software's Loss -- Market Talk

14 jul 2025, 20:05 UTC

Marktinformatie

Adobe and Salesforce May Struggle to Keep Up With AI Agents -- Market Talk

14 jul 2025, 19:11 UTC

Marktinformatie

Oil Retreats Despite Trump Threats of Russia Sanctions -- Market Talk

14 jul 2025, 19:09 UTC

Marktinformatie

Gold Breaks a 3-Day Win Streak -- Market Talk

14 jul 2025, 18:59 UTC

Marktinformatie

Hotter Weather Outlook, LNG Flows Boost U.S. Natural Gas -- Market Talk

14 jul 2025, 18:30 UTC

Acquisities, Fusies, Overnames

Synopsys Buy of Ansys Gets China OK. The $35 Billion Deal Is Set to Close. -- Barrons.com

14 jul 2025, 18:25 UTC

Marktinformatie

Dollar Gains, Treasury Yields Lose Steam as Trump Threatens Russia -- Market Talk

14 jul 2025, 18:25 UTC

Marktinformatie

Global Forex and Fixed Income Roundup: Market Talk

14 jul 2025, 16:59 UTC

Marktinformatie

Goldman Sachs Lifts 2H25 Crude Price Views -- Market Talk

14 jul 2025, 16:53 UTC

Populaire aandelen

Stocks to Watch Monday: Kenvue, Tesla, Synopsys, Robinhood -- WSJ

14 jul 2025, 16:27 UTC

Marktinformatie

Oil Falls as Investors Monitor U.S.-EU Trade, Trump's Russia Sanction Threats -- Market Talk

14 jul 2025, 16:20 UTC

Marktinformatie
Winsten

Auto & Transport Roundup: Market Talk

14 jul 2025, 16:20 UTC

Marktinformatie

Basic Materials Roundup: Market Talk

14 jul 2025, 16:15 UTC

Marktinformatie

Global Commodities Roundup: Market Talk

14 jul 2025, 16:12 UTC

Marktinformatie
Acquisities, Fusies, Overnames

Waters Closer to Thermo Fisher, Danaher With Becton Dickinson Unit -- Market Talk

Peer Vergelijking

Prijswijziging

Bio-Rad Laboratories Inc Prognose

Koersdoel

By TipRanks

28.78% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 323 USD  28.78%

Hoogste 387 USD

Laagste 245 USD

Gebaseerd op 4 Wall Street-analisten die 12-maands prijsdoelen bieden voor Bio-Rad Laboratories Inc - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Strong Buy

4 ratings

3

Buy

1

Hold

0

Sell

Technische score

By Trading Central

229.835 / 235.8095Steun & Weerstand

Korte Termijn

Very Strong Bearish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Sentiment

By Acuity

148 / 376 Rangschikking in Gezondheidszorg

Nieuwssentiment

Neutral

Volatiliteit

Onder gemiddelde

Nieuws Volume (RCV)

Onder gemiddelde

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Bio-Rad Laboratories Inc

Bio-Rad Laboratories, Inc. manufactures and distributes life science research and clinical diagnostic products in the United States, Europe, Asia, Canada, and Latin America. It operates through two segments, Life Science and Clinical Diagnostics. The company develops, manufactures, and markets instruments, systems, reagents, and consumables to separate, purify, characterize, and quantitate biological materials such as cells, proteins, and nucleic acids for proteomics, genomics, biopharmaceutical production, cellular biology, and food safety markets. It also designs, manufactures, markets, and supports test systems, informatics systems, test kits, and specialized quality controls for hospitals, diagnostic reference, transfusion, and physician office laboratories. The company offers its products through its direct sales force, as well as through distributors, agents, brokers, and resellers. Bio-Rad Laboratories, Inc. was founded in 1952 and is headquartered in Hercules, California.